Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · June 17, 2015

Oligometastatic RCC With Favorable Risk Factors

Written by
Heather R Greene MSN, FNP, AOCNP

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Heather Greene MSN, FNP, AOCNP

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bradley Somer MD

    Bradley G. Somer MD

    Jun 18, 2015

    On the one hand, this patient is low risk by prognostic criteria with locally treated oligometastatic disease. On the other hand, bone disease seems to be biologically more aggressive.  In light of this, and the morbidities associated with skeletal metastases, I would consider starting treatment with a VEGF targeted therapy with sunitinib or pazopanib. Additionally, consideration of a bone resorptive agent to prevent skeletal related events should be given. 

  • Ricardo Bulnes

    Jun 20, 2015

    She need  treatment  with aTKI

  • Mayer Gorbaty

    Jun 20, 2015

    I agree with the bone directed therapy i.e. denosumab or zolendronic acid.  I would be hesitant about however the VEGF targeted therapy in this 79 year old.  Instead I may reimage him- bone and body- in 3-4 months.  If he still has only the one parietal bone lesion I would then irradiate it.  If he has blossomed with full blown widely progressive disease then I would start additional systemic therapy.

  • Apr 18, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated